Hazardous drugs

Occupational Medicine - State of the Art Reviews

Volumn 12, Issue 4, 1997, Pages 669-685

  Black, Lisa A ^a   Presson, Angela C ^a,b,c  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Occupational Safety and Health Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DANGEROUS GOODS; ENGINEERING; GOVERNMENT; HEALTH CARE PERSONNEL; HEALTH SURVEY; HOSPITAL PHARMACY; HUMAN; OCCUPATIONAL EXPOSURE; PROTECTIVE EQUIPMENT; REVIEW; UNITED STATES;

ENGINEERING; HAZARDOUS SUBSTANCES; HEALTH PERSONNEL; HUMANS; OCCUPATIONAL EXPOSURE; PHARMACEUTICAL PREPARATIONS; PHARMACY SERVICE, HOSPITAL; POPULATION SURVEILLANCE; PROTECTIVE DEVICES; UNITED STATES; UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION;

EID: 33748962032     PISSN: 0885114X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (202)

1. Aisenberg AC: Acute nonlymphocytic leukemia after treatment tor Hodgkin's disease. Am J Med 75:449-454, 1983.
2. American Medical Association Council on Scientific Affairs: Guidelines for handling parenteral antineoplastics. JAMA 253:1590-1592, 1985.
3. American National Standards Institute: Occupational and Educational Eye and Face Protection. New York, ANSI Z87.1, 1968.
4. American Society of Hospital Pharmacists: ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm 47:1033-1049, 1990.
5. Andersen R, Boedicker M, Ma M, Goldstein EJC: Adverse reactions associated with pentamidine isethionate in AIDS patients: Recommendations for monitoring therapy. Drug Intell Clin Pharm 20:862-868, 1986.
6. Anderson RW, Puckett WH, Dana WJ, et al: Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 39:1881-1887, 1982.
7. Anwar WA, Salama SI, El Serafy MM, et al: Chromosomal aberrations and micronucleus frequency in nurses occupationally exposed to cytotoxic drugs. Mutagenesis 9:315-317, 1994.
8. Arrington DM, McDiarmid MA: Comprehensive program for handling hazardous drugs. Am J Hosp Pharm 50:1170-1174, 1993.
9. Avis KE, Levchuck JW: Special considerations in the use of vertical laminar flow workbenches. Am J Hosp Pharm 41:81-87, 1984.
10. Balmes JR, Estacio PL, Quinlan P, et al: Respiratory effects of occupational exposure to aerosolized pentamidine. J Occup Environ Med 37:145-150, 1995.
11. Barale R, Sozzi G, Tonio P, et al: Sister-chromatid exchanges in lymphocytes and mutagenicity in urine of nurses handling cytotoxic drugs. Mutat Res 157:235-240, 1985.
12. Barber RK: Fetal and neonatal effects of cytotoxic agents. Obstet Gynecol 51:41S-47S, 1981.
13. Beeley L: Drugs in early pregnancy. J Pharmacol Ther 1:189-198, 1978.
14. Benhamou S, Pot-Deprun J, Sancho-Garnier H, Chouroulinkov I: Sister chromatid exchanges and chromosomal aberrations in lymphocytes of nurses handling cytostatic drugs. Int J Cancer 41:350-353, 1988.
15. Boice JD, Greene, MH, Killen JY, et al: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine(methyl-ccnu). N Engl J Med 309:1079-1084, 1983.
16. Bos RP, Leenars AO, Theuws JL, Henderson PT: Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health 50:359-369, 1982.
17. Bradley JS, Bastian JF, Connor JD: [letter]. JAMA 262:1948, 1989.
18. Brumen V, Horvat D, Trosic I: Potential genotoxic risk related to simultaneous exposure to radionuclides and cytostatics. Am J Ind Med 27:871-876, 1995.
19. Bryan D, Marback RC: Laminar-airflow equipment certification: What the pharmacist needs to know. Am J Hosp Pharm 41:1343-1349, 1984.
20. Burgaz S, Ozdamar YN, Karakaya AE: A signal assay for the detection of genotoxic compounds: Application on the urines of cancer patients on chemotherapy and of nurses handling cytotoxic drugs. Hum Toxicol 7:557-560, 1988.
21. California Department of Health Services Occupational Health Surveillance and Evaluation Program: Health care worker exposure to ribavirin aerosol: Field investigation Fl-86-009. Berkeley, CA, California Department of Health Services, 1986.
22. Castegnaro M, Adams J, Armour MA, et al (eds): Laboratory decontamination and destruction of carcinogens in laboratory wastes: Some antineoplastic agents. International Agency for Research on Cancer. Lyon, France, IARC, 1985, scientific publication 73.
23. Chabner BA: Second neoplasm - a complication of cancer chemotherapy. N Engl J Med 297:213-5, 1977.
24. Chapman RM: Effect of cytotoxic therapy on sexuality and gonadal function. In Perry MC, Yarbro JW (eds): Toxicity of Chemotherapy. Orlando, Grune & Stratton, 1984, pp 343-363.
25. Chen CH, Vazquez-Padua M, Cheng YC: Effect of antihuman immunodeficiency virus nucleoside analogs on mDNA and its implications for delayed toxicity. Mol Pharmacol 39:625-628, 1990.
26. Christensen CJ, Lemasters GK, Wakeman MA: Work practices and policies of hospital pharmacists preparing antineoplastic agents. J Occup Med 32:508-512, 1990.
27. Chrysostomou A, Morley AA, Seshadri R: Mutation frequency in nurses and pharmacists working with cytotoxic drugs. Aust N Z J Med 14:831-834, 1984.
28. Connor JD, Hintz M, Van Dyke R: Ribavirin pharmacokinetics in children and adults during therapeutic trials. In Smith RA, Knight V, Smith JAV (eds): Clinical Applications of Ribavirin. Orlando, Academic Press, 1984.
29. Connor TH, Laidlaw JL, Theiss JC, et al: Permeability of latex and polyvinyl chloride gloves to carmustine. Am J Hosp Pharm 41:676-679, 1984.
30. Conover B, Goldsmith, JC, Buehler, BA, et al: Aerosolized pentamidine and pregnancy. Ann Int Med 109:927, 1988.
31. Cooke J, Williams J, Morgan RJ, et al: Use of cytogenetic methods to determine mutagenic changes in the blood of pharmacy personnel and nurses who handle cytotoxic agents. Am J Hosp Pharm 48:1199-1205, 1991.
32. Crudi CB: A compounding dilemma: I've kept the drug sterile but have I contaminated myself? Natl Intravenous Therapy J 3:77-80, 1980.
33. Decker JA, Seitz TA, Shults RA, et al: Occupational exposure to aerosolized pharmaceuticals and control strategies. Scand J Work Environ Health 18(suppl 2):100-102, 1992.
34. De Méo MP, Mérono S, DeBaille AD, et al: Monitoring exposure of hospital personnel handling cytotoxic drugs and contaminated materials. Int Arch Occup Environ Health 66:363-368, 1995.
35. Dole v. United Steelworkers. 494 U.S.26, 1990.
36. Doll DC: Aerosolised pentamidine [letter]. Lancet 2(8674):1284-1285, 1989.
37. Drugs that can cause cancer [editorial]. Lancet 1:261-262, 1984.
38. Duvall E, Baumann B: An unusual accident during the administration of chemotherapy. Cancer Nurs 3:305-306, 1980.
39. Ensslin AS, Stoll Y, Pethran A, et al: Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med 51:229-233, 1994.
40. Environmental Protection Agency: Discarded commercial chemical products, off specification species, container residues, and spill residues thereof. 40 CFR 261.33(f), 1991.
41. Evelo CTA, Bos RP, Peters JGP, Henderson PT: Urinary phosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health 58:151-155, 1986.
42. Everson RB, Ratcliffe JM, Flack PM, et al: Detection of low levels of urinary mutagen excretion by chemotherapy workers which was not related to occupational drug exposures. Cancer Res 45:6487-6497, 1985.
43. Fackler JC, Flannery K, Zipkin M, McIntosh K: Precautions in the use of ribavirin at the children's hospital. N Engl J Med 322:634, 1990.
44. Falck K, Grohn P, Sorsa M, et al: Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1(8128):1250-1251, 1979.
45. Falck K, Sorsa M, Vainio H: Use of the bacterial fluctuation test to detect mutagenicity in urine of nurses handling cytostatic drugs [abstract]. Mutat Res 85:236-237, 1981.
46. Ferguson LR, Everts R, Robbie MA, et al: The use within New Zealand of cytogenetic approaches to monitoring of hospital pharmacists for exposure to cytotoxic drugs: Report of a pilot study in Auckland. Aust J Hosp Pharm 18:228-233, 1988.
47. Fuchs J, Hengstler JG, Jung D, et al: DNA damage in nurses handling antineoplastic agents. Mutat Res 342:17-23, 1995.
48. Garrett MJ: Teratogenic effects of combination chemotherapy [letter]. Ann Intern Med 80:667, 1974.
49. Gebhart E, Windolph B, Wopfner F: Chromosome studies on lymphocytes of patients under cytostatic therapy, II. Studies using the BUDR-labelling technique in cytostatic interval therapy. Hum Genet 56:157-167.
50. Gililland J, Weinstein L: The effects of cancer chemotherapeutic agents on the developing fetus. Obstet Gynecol Surv 38:6-13, 1983.
51. Gilman GA, Rall TW, Nies AS, Taylor P (eds): The Pharmacological Basis of Therapeutics, 8th ed. New York, Pergamon Press, 1990.
52. Gladu JM, Ecobichon DJ: Evaluation of exposure of health care personnel to ribavirin. J Toxicol Environ Health 28:1-12, 1989.
53. Gold EB, Tomich E: Occupational hazards to fertility and pregnancy outcome. State Art Rev Occup Med 9:435-469, 1994.
54. Goloni-Bertollo EM, Tajara EH, Manzato AJ, Varella-Garcia M: Sister-chromatid exchanges and chromosome aberrations in lymphocytes of nurses handling antineoplastic drugs. Int J Cancer 50:341-344, 1992.
55. Green ST, Nathwani D, Christie PR, Kennedy DH: Aerosolized pentamidine [letter]. Lancet 2(8674):1284, 1989.
56. Greene MH, Boice JD, Greer BE, et al: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N Engl J Med 307:1416-1421, 1982.
57. Grummt T, Grummt HJ, Schott G: Chromosomal aberrations in peripheral lymphocytes of nurses and physicians handling antineoplastic drugs. Mutat Res 302:19-24, 1993.
58. Gude JK: Selective delivery of pentamidine to the lung by aerosol [letter]. Am Rev Respir Dis 139:1060, 1989.
59. Guglielmo BJ, Jacobs RA, Locksley RM: The exposure of health care workers to ribavirin aerosol. JAMA 261:1880-1881, 1989.
60. Gunstream SR, Seidenfeld JJ, Sobonya RE, McMahon LJ: Mitomycin-associated lung disease. Cancer Treat Rep 67:301-304, 1983.
61. Haas JF, Kittelmann B, Mehnert WH, et al: Risk of leukemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer 55:213-218, 1987.
62. Hansen J, Olsen JH: Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health 20:22-26, 1994.
63. Harris CC: Immunosuppressive anticancer drugs in man: Their oncogenic potential. Radiology 114:163-166, 1975.
64. Harris CC: The carcinogenicity of anticancer drugs: A hazard in man. Cancer 37:1014-1023, 1976.
65. Harrison R, Bellows J, Rempel D, et al: Assessing exposures of health-care personnel to aerosols of ribavirin-California. MMWR 37:560-563, 1988.
66. Hazards of cancer chemotherapy [editorial]. Lancet 2(8311):1317-1318, 1982.
67. Hemminki K, Kyyronen P, Lindbohm ML: Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J Epidemiol Community Health 39:141-147, 1985.
68. Henderson, DK, Gerberding JL: Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis. J Infect Dis 160:321-327, 1989.
69. Herr GE, McDiarmid MA, Testa MJ, Caldwell DJ: Health hazards to healthcare workers. In Deeter D, Gaydos J (eds): Occupational Health: The Soldier and the Industrial Base. Washington, DC, TMM Publications, 1993, pp 129-163.
70. Hillyard IW: The preclinical toxicology and safety of ribavirin. In Smith RA, Kirkpatrick W (eds): Ribavirin: A Broad Spectrum Antiviral Agent. New York, Academic Press, 1980.
71. Hirst M, Tse S, Mills DG, et al: Occupational exposure to cyclophosphamide. Lancet 1(8370):186-188, 1984.
72. Hoover R, Fraumeni JF: Drug-induced cancer. Cancer 47:1071-1080, 1981.
73. Hoy RH, Stump LM: Effect of an air-venting filter device on aerosol production from vials. Am J Hosp Pharm 41:324-326, 1984.
74. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Aziridines, N-, S-, and O-mustards and Selenium. Lyon, France, IARC, 1975.
75. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man: Some Naturally Occurring Substances. Vol 10. Lyon, France, IARC, 1976.
76. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Some Antineoplastic and Immunosuppressive Agents. Vol 26. Lyon, France, IARC, 1981.
77. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Chemicals, Industrial Processes and Industries Associated with Cancer in Humans. Vols 1-29(Suppl 4). Lyon, France, IARC, 1982.
78. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Genetic and Related Effects: An Updating of Selected IARC Monographs from Volumes 1-42. Vols 1-42(Suppl 6). Lyon, France, IARC, 1987.
79. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. Vols 1-42(Suppl 7). Lyon, France, IARC, 1987.
80. International Agency for Research on Cancer: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Pharmaceutical Drugs. Vol 50. Lyon, France, IARC, 1990.
81. Jagun O, Ryan M, Waldron HA: Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet 1(8295):443-444, 1982.
82. Johnson EG, Janosik JE: Manufacturers' recommendations for handling spilled antineoplastic agents. Am J Hosp Pharm 46:318-319, 1989.
83. Jones RB, Frank R, Mass T: Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center. CA Cancer J Clin 33:258-263, 1983.
84. Juma FD, Rogers HJ, Trounce JR, Bradbrook ID: Pharmacokinetics of intravenous cyclophosphamide in man, estimated by gas-liquid chromatography. Cancer Chemother Pharmacol 1:229-231, 1978.
85. Kacmarek RM: Ribavirin and pentamidine aerosols: Caregiver beware! Respir Care 35:1034-1036, 1990.
86. Karakaya AE, Burgaz S, Bayhan A: The significance of urinary thioethers as indicators of exposure to alkylating agents. Arch Toxicol 13(suppl):117-119, 1989.
87. Kilham L, Ferm VH: Congenital anomalies induced in hamster embryos with ribavirin. Science 195:413-4, 1977.
88. Kleinberg ML, Quinn MJ: Airborne drug levels in a laminar flow hood. Am J Hosp Pharm 38:1301-1303, 1981.
89. Kolmodin-Hedman B, Hartvig P, Sorsa M, Falck K: Occupational handling of cytostatic drugs. Arch Toxicol 54:25-33, 1983.
90. Kriebel D, Commoner B, Bollinger D, et al: Detection of occupational exposure to genotoxic agents with a urinary mutagen assay. Mutat Res 108:67-79, 1983.
91. Kyle RA: Second malignancies associated with chemotherapy. In Perry MC, Yarbro JW (eds): Toxicity of Chemotherapy. Orlando, Grune & Stratton, 1984, pp 479-506.
92. Laidlaw JL, Connor TH, Theiss JC, et al: Permeability of latex and polyvinyl chloride gloves to 20 antineoplastic drugs. Am J Hosp Pharm 41:2618-2623, 1984.
93. Laidlaw JL, Connor TH, Theiss JC, et al: Permeability of four disposable protective-clothing materials to seven antineoplastic drugs. Am J Hosp Pharm 42:2449-2454, 1985.
94. Lambert B, Ringborg U, Harper E, Linblod A: Sister-chromatid exchanges in lymphocyte cultures of patients receiving chemotherapy for malignant disorders. Cancer Treat Rep 62:1413-1419, 1978.
95. Lee SB: Ribavirin - exposure to health care workers. Am Ind Hyg Assoc J 49:A13-A14, 1988.
96. LeRoy ML, Roberts MJ, Theisen JA: Procedures for handling antineoplastic injections in comprehensive cancer centers. Am J Hosp Pharm 40:601-603, 1983.
97. Linet MS, McLaughlin JK, Malker HSR, et al: Occupation and hematopoietic and lymphoproliferative malignancies among women: A linked registry study. J Occup Med 36:1187-1198, 1994.
98. Lunn G, Sansone EB: Validated methods for handling spilled antineoplastic agents [letter]. Am J Hosp Pharm 46:1131, 1989.
99. Lunn G, Sansone EB, Andrews AW, Hellwig LC: Degradation and disposal of some antineoplastic drugs. J Pharm Sci 78:652-659, 1989.
100. Machado-Santelli GM, Cerqueira EM, Oliveira CT, deBraganca-Pereira CAA: Biomonitoring of nurses handling antineoplastic drugs. Mutat Res 322:203-208, 1994.
101. Mahon SM, Casperson DS, Yackzan S, et al: Safe handling practices of cytotoxic drugs: The results of a chapter survey. Oncol Nurs Forum 21:1157-1165, 1994.
102. Marquardt H, Marquardt H: Induction of malignant transformation and mutagenesis in cell cultures by cancer chemotherapeutic agents. Cancer 40:1930-1934, 1977.
103. Matthews T, Boehme R: Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 10(suppl 3) S490-S494, 1988.
104. McDevitt JJ, Lees PSJ, McDiarmid MA: Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occup Med 35:57-60, 1993.
105. McDiarmid MA, Egan T, Furio M, et al: Sampling tor airborne fluorouracil in a hospital drug preparation area. Am J Hosp Pharm 43:1942-1945, 1986.
106. McDiarmid MA, Emmett EA: Biological monitoring and medical surveillance of workers exposed to antineoplastic agents. Semin Occup Med 2:109-117, 1987.
107. McDiarmid MA, Jacobson-Kram D: Aerosolized pentamidine and public health. Lancet 2(8667): 863-864, 1989.
108. McDiarmid MA: Medical surveillance for antineoplastic-drug handlers. Am J Hosp Pharm 47:1061-1066, 1990.
109. McDiarmid MA, Gurley HT, Arrington D: Pharmaceuticals as hospital hazards: Managing the risks. J Occup Med 33:155-158, 1991.
110. McDiarmid MA, Kolodner K, Humphrey F, et al: Baseline and phosphoramide mustard-induced sister-chromatid exchanges in pharmacists handling anti-cancer drugs. Mutat Res 279:199-204, 1992.
111. McDiarmid MA, Schaefer J, Richard CL, et al: Efficacy of engineering controls in reducing occupational exposure to aerosolized pentamidine. Chest 102:1764-1766, 1992.
112. McDiarmid MA: Occupational exposure to pharmaceuticals: Antineoplastics, anesthetic agents, sex steroid hormones. In Paul M (ed): Occupational and Environmental Reproductive Hazards: A Guide for Physicians. Baltimore, Williams & Wilkens, 1993, pp 280-295.
113. McDiarmid MA, Presson AC, Weaver V, Fujikawa J: Controlling occupational exposure to hazardous drugs. Am J Health Syst Pharm 53:1669-1685, 1996.
114. McEvoy GK (ed): American Hospital Formulary Service Drug Information. Bethesda, MD, American Society of Hospital Pharmacists, 1993.
115. McLendon BF, Bron AF: Corneal toxicity from vinblastine solution. Br J Ophthalmol 62:97-99, 1978.
116. Milkovic-Kraus S, Horvat D: Chromosomal abnormalities among nurses occupationally exposed to antineoplastic drugs. Am J Ind Med 19:771-774, 1991.
117. Milkovic-Kraus S, Kraus O, Krsnjavi H, Kubelka D: Environmental effects in oncology and radiology department personnel. Prev Med 21:498-502, 1992.
118. Montgomery AB, Corkery KJ, Brunette ER, et al: Occupational exposure to aerosolized pentamidine. Chest 98:386-388, 1990.
119. National Sanitation Foundation. Standard No. 49 for Class II (Laminar Flow) Biohazard Cabinetry. Ann Arbor, MI, National Sanitation Foundation, 1990.
120. National Study Commission on Cytotoxic Exposure: Recommendations for Handling Cytotoxic Agents. Providence, RI, Rhode Island Hospital, 1983.
121. National Study Commission on Cytotoxic Exposure: Consensus Responses to Unresolved Questions Concerning Cytotoxic Agents. Providence, RI, Rhode Island Hospital, 1984.
122. National Study Commission on Cytotoxic Exposure: Recommendations for Handling Cytotoxic Agents. Providence, RI, Rhode Island Hospital, 1987.
123. Naumann BD, Sargent EV, Starkman BS, et al: Performance-based exposure control limits for pharmaceutical active ingredients. Am Ind Hyg Assoc J 57:33-42, 1996.
124. Neal AD, Wadden RA, Chiou WL: Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 40:597-601, 1983.
125. Newman MA, Valanis BG, Schoeny RS, Hee SQ: Urinary biological monitoring markers of anticancer drug exposure in oncology nurses. Am J Public Health 84:852-855, 1994.
126. Nguyen TV, Theiss JC, Matney TS: Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 42: 4792-4796, 1982.
127. Nikula E, Kiviniitty K, Leisti J, Taskinen P: Chromosome aberrations in lymphocytes of nurses handling cytostatic agents. Scand J Work Environ Health 10:71-74, 1984.
128. Norppa H, Sorsa M, Vainio H, et al: Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 6:299-301, 1980.
129. Palmer RG, Dore CJ, Denman AM: Chlorambucil-induced chromosome damage to human lymphocytes is dose-dependent and cumulative. Lancet 1(8371):246-249, 1984.
130. Parillo VL: Documentation forms for monitoring occupational surveillance of healthcare workers who handle cytotoxic drugs. Oncol Nurs Forum 21:115-120, 1994.
131. Penn I: Second malignant neoplasms associated with immunosuppressive medications. Cancer 37:1024-1032, 1976.
132. Perry MC, Yarbro JW (eds): Toxicity of Chemotherapy. Orlando, Grune & Stratton, 1984.
133. Physician's Desk Reference: Oradell, NJ, Medical Economics Data, 1991.
134. Pohlova H, Cerna M, Rossner P: Chromosomal aberrations, SCE and urine mutagenicity in workers occupationally exposed to cytostatic drugs. Mutat Res 174:213-217, 1986.
135. Power LA, Anderson RW, Cortopassi R, et al: Update on safe handling of hazardous drugs: The advice of experts. Am J Hosp Pharm 47:1050-1060, 1990.
136. Poyen D, DeMéo MP, Botta A, et al: Handling of cytostatic drugs and urine mutagenesis. Int Arch Occup Environ Health 61:183-188, 1988.
137. Pyy L, Sorsa M, Hakala E: Ambient monitoring of cyclophosphamide in manufacture and hospitals. Am Ind Hyg Assoc J 49:314-317, 1988.
138. Reich SD, Bachur NR: Contact dermatitis associated with adriamycin (NSC-123127) and daunorubicin (NSC-82151). Cancer Chemother Rep 59:677-678, 1975.
139. Reimer RR, Hoover R, Fraumeni JF, Young RC: Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med 297:177-181, 1977.
140. Reynolds RD, Ignoffo R, Lawrence J, et al: Adverse reactions to AMSA in medical personnel. Cancer Treat Rep 66:1885, 1982.
141. Rodriguez WJ, Dang Bui RH, Connor JD, et al: Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections. Antimicrob Agents Chemother 31:1143-1146, 1987.
142. Rogers B: Health hazards to personnel handling antineoplastic agents. Occup Med State Art Rev 2:513-524, 1987.
143. Rogers B, Emmett EA: Handling antineoplastic agents: Urine mutagenicity in nurses. IMAGE Journal of Nursing Scholarship 19:108-113, 1987.
144. Rogers B: Work practices of nurses who handle antineoplastic agents. AAOHN J 35:24-31, 1987.
145. Rosner F: Acute leukemia as a delayed consequence of cancer chemotherapy. Cancer 37:1033-1036, 1976.
146. Rudolph R, Suzuki M, Luce JK: Experimental skin necrosis produced by adriamycin. Cancer Treat Rep 63:529-537, 1979.
147. Schafer AL: Teratogenic effects of antileukemic therapy. Arch Int Med 141:514-515, 1981.
148. Schmähl D: Carcinogenic action of anticancer drugs with special reference to immunosuppression. Cancer 40:1927-1929, 1977.
149. Selevan SG, Lindbolm ML, Hornung RW, Hemminki K: A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med 313:1173-1178, 1985.
150. Sessink PJM, Boer KA, Scheefhals APH, et al: Occupational exposure to antineoplastic agents at several departments in a hospital. Int Arch Occup Environ Health 64:105-112, 1992.
151. Sessink PJM, Timmersmans JL, Anzion RBM, Bos RP: Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. J Occup Med 36:79-83, 1994.
152. Sessink PJM, Cerná M, Rössner P, et al: Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res 309:193-199, 1994.
153. Shortridge LA, Lemasters GK, Valanis B: Menstrual cycles in nurses handling antineoplastic drugs Cancer Nurs 18:439-444, 1995.
154. Shults RA, Baron S, Decker J, et al: Health care worker exposure to aerosolized ribavirin: Biological and air monitoring. J Occup Environ Med 38:257-263, 1996.
155. Sieber SM: Cancer chemotherapeutic agents and carcinogenesis. Cancer Chemother Rep 59:915-918, 1975.
156. Sieber SM, Adamson RP: Toxicity of antineoplastic agents in man: Chromosomal aberrations, antifertility effects, congenital malformations, and carcinogenic potential. Adv Cancer Res 22:57-155, 1975.
157. Siebert D, Simon U: Cyclophosphamide: Pilot study of genetically active metabolites in the urine of a treated human patient. Mutat Res 19:65-72, 1973.
158. Skov T, Lynge E, Maarup B, et al: Risks for physicians handling antineoplastic drugs [letter]. Lancet 336:1446, 1990.
159. Skov T, Maarup B, Olsen J, et al: Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 49:855-861, 1992.
160. Slevin ML, Ang LM, Johnston A, Turner P: The efficiency of protective gloves used in the handling of cytotoxic drugs. Cancer Chemother Pharmacol 12:151-153, 1984.
161. Smaldone GC, Vincicuerra C, Marchese J: Detection of inhaled pentamidine in health care workers. N Engl J Med 325:891-892, 1991.
162. Sorsa M, Hemminki K, Vainio H: Occupational exposure to anticancer drugs - Potential and real hazards. Mutat Res 154:135-149, 1985.
163. Sorsa M, Pyy L, Salomaa S, et al: Biological and environmental monitoring of occupational exposure to cyclophosphamide in industry and hospitals. Mutat Res 204:465-479, 1988.
164. Sotaniemi EA, Sutinen S, Arranto AJ, et al: Liver damage in nurses handling cytostatic agents. Acta Med Scand 214:181-189, 1983.
165. Staiano N, Gallelli JF, Adamson RH, Thorgeirsson SS: Lack of urine mutagenic activity in urine from hospital phamacists admixing antitumor drugs. Lancet 1(8220):615-616, 1981.
166. Stansbury M: Reactive airways dysfunction syndrome in a nurse exposed to pentamidine [letter]. J Occup Environ Med 38:330-331, 1996.
167. Stellman JM: The spread of chemotherapeutic agents at work: Assessment through stimulation. Cancer Invest 5:75-81, 1987.
168. Stephens JD, Golbus MS, Miller TR, et al: Multiple congenital abnormalities in a fetus exposed to 5-fluorouracil during the first trimester. Am J Obstet Gynecol 137:747-749, 1980.
169. Stiller A, Obe G, Boll I, Pribilla W: No elevation of the frequencies of chromosomal aberrations as a consequence of handling cytostatic drugs. Mutat Res 121:253-259, 1983.
170. Stoikes ME, Carlson JD, Farris FF, Walker PR: Permeability of latex and polyvinyl chloride gloves to fluorouracil and methotrexate. Am J Hosp Pharm 44:1341-1346, 1987.
171. Stolar MH, Power LA, Viele CS: Recommendations for handling cytotoxic drugs in hospitals. Am J Hosp Pharm 40:1163-1171, 1983.
172. Stücker I, Hirsch A, Doloy T, et al: Urine mutagenicity, chromosomal abnormalities and sister chromatid exchanges in lymphocytes of nurses handling cytostatic drugs. Int Arch Occup Environ Health 57:195-205, 1986.
173. Stücker I, Caillard JF, Collin R, et al: Risk of spontaneous abortion among nurses handling antineoplastic drugs. Scand J Work Environ Health 16:102-107, 1990.
174. Thomas SHL, Page CM, O'Doherty MJ, Bateman NT: Aerosolized pentamidine [letter]. Lancet 2(8674):1284, 1989.
175. Thiringer G, Granung G, Holmén A, et al: Comparison of methods for the biomonitoring of nurses handling antitumor drugs. Scand J Work Environ Health 17:133-138, 1991.
176. Timbrell JA: Principles of Biochemical Toxicology. 2nd ed. London, Taylor & Francis, 1991.
177. Tortorici M: Precautions followed by personnel involved with the preparation of parenteral antineoplastic medications. Hosp Pharm 15:293-301, 1980.
178. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988.
179. U.S. Department of Health and Human Services: Recommendations for the Safe Handling of Cytotoxic Drugs. Bethesda, MD, National Institutes of Health, 1992, NIH publication 92-2621.
180. U.S. Department of Health and Human Services: NIOSH Guidelines for Protecting the Safety and Health of Health Care Workers. Cincinatti, National Institute for Occupational Safety and Health, 1988, publication 88-119.
181. U.S. Department of Labor, Occupational Safety and Health Administration: Respiratory protection standard. 29 CFR 1910.134, 1984.
182. U.S. Department of Labor, Occupational Safety and Health Administration: Work Practice Guidelines for Personnel Dealing with Cytotoxic (Antineoplastic) Drugs. Washington, DC, OSHA, 1986, publication 8-1.1.
183. U.S. Department of Labor, Occupational Safety and Health Administration: Hazard communication standard. 29 CFR 1910.1200, as amended February 9, 1994, (1989).
184. U.S. Department of Labor, Occupational Safety and Health Administration: Access to employee and medical records standard. 29 CFR 1910.20, 1990.
185. U.S. Department of Labor, Occupational Safety and Health Administration: Occupational exposure to bloodborne pathogens standard. 29 CFR 1910.1030, 1991.
186. U.S. Department of Labor, Occupational Safety and Health Administration: OSHA Technical Manual. OSHA Instruction TED 1.15. Washington, DC, OSHA, 1995.
187. Vaccari FL, Tonat K, DeChristoforo R, et al: Disposal of antineoplastic wastes at the NIH. Am J Hosp Pharm 41:87-92, 1984.
188. Vainio H: Inhalation anesthetics, anti-cancer drugs and sterilants as chemical hazards in hospitals. Scand J Work Environ Health 8:94-107, 1982.
189. Valanis B, Shortridge L: Self protective practices of nurses handling antineoplastic drugs. Oncol Nurs Forum 14:23-27, 1987.
190. Valanis BG, Hertzberg V, Shortridge L: Antineoplastic drugs - handle with care. AAOHN J 35:487-492, 1987.
191. Valanis B, Driscoll K, McNeil V: Comparison of antineoplastic drug handling policies of hospitals with OSHA guidelines: A pilot study. Am J Public Health 80:480-481, 1990.
192. Valanis B, Vollmer WM, Labuhn K, et al: Antineoplastic drug handling protection after OSHA guidelines: Comparison by profession, handling activity, and work site. J Occup Med 34:149-55, 1992.
193. Van Raalte J, Rice C, Moss CE: Visible-light system for detecting doxorubicin contamination on skin and surfaces. Am J Hosp Pharm 47:1067-1074, 1990.
194. Venitt S, Crofton-Sleigh C, Hunt J, et al: Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: Urinary mutation assays and urinary platinum as markers of absorption. Lancet 1(8368):74-76, 1984.
195. Waksvik H, Klepp O, Brogger A: Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rep 65:607-610, 1981.
196. Wall RL, Clausen KP: Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med 293:271-273, 1975.
197. Weisburger JH, Griswold DP, Prejean JD, et al: Tumor induction by cytostatics. The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. Recent Results Cancer Res 52:1-17, 1975.
198. Widström J, Edling C: Antineoplastic agents. In Brune DK, Endling C (eds): Occupational Hazards in the Health Professions. Boca Raton, FL, CRC Press, 1989, pp 132-139.
199. Wilson JP, Solimando DA: Aseptic technique as a safety precaution in the preparation of antineoplastic agents. Hosp Pharm 16:575-581, 1981.
200. Wong RJ: Glove selection for handling cytotoxic and hazardous drugs [letter]. Am J Hosp Pharm 47:2459, 1990.
201. Yodaiken RE, Bennett D: OSHA work-practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm 43:1193-1204, 1986.
202. Zimmerman PF, Larsen RK, Barkley EW, Gallelli JF: Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm 38:1693-1695, 1981.